What is the recommended treatment approach for psoriatic arthritis, including first-line NSAIDs, conventional synthetic disease-modifying antirheumatic drugs, and biologic therapies?

Psoriatic Arthritis Treatment Approach

For psoriatic arthritis, initiate treatment with NSAIDs for symptom relief, followed by conventional synthetic DMARDs (methotrexate, sulfasalazine, or leflunomide) as first-line disease-modifying therapy, with early escalation to biologic DMARDs (TNF inhibitors, IL-17 inhibitors, or IL-23 inhibitors) or targeted synthetic DMARDs (JAK inhibitors) within 12-24 weeks if inadequate response is achieved. 1

Treatment Algorithm

Initial Assessment

Evaluate disease activity across all domains (peripheral arthritis, axial disease, enthesitis, dactylitis, skin psoriasis, nail disease) and identify comorbidities that influence drug selection 1.

First-Line Therapy

For Peripheral Arthritis:

• NSAIDs for symptomatic relief (conditionally recommended) 2
• Conventional synthetic DMARDs (csDMARDs) as disease-modifying therapy:
  • Methotrexate (most commonly used)
  • Sulfasalazine
  • Leflunomide 1

Critical timing consideration: While csDMARDs are strongly recommended for accessibility and observational data support, high-quality evidence demonstrates TNF inhibitors are superior to csDMARDs as first-line therapy, particularly in early disease 2. The decision to use TNF inhibition first-line should involve shared decision-making considering risks, benefits, and patient preference.

Escalation Timeline

• Assess clinical response every 12-24 weeks
• Escalate therapy between 12-24 weeks if inadequate response 2

Second-Line Therapy (Advanced DMARDs)

When csDMARDs fail or for expedited treatment routes, the following are approved:

Biologic DMARDs (bDMARDs):

1. TNF inhibitors:

   • Adalimumab
   • Certolizumab
   • Etanercept
   • Infliximab
   • Golimumab 1

2. IL-17 pathway inhibitors:

   • IL-17A: Secukinumab, Ixekizumab
   • IL-17A/F: Bimekizumab 1

3. IL-23 inhibitors:

   • Guselkumab
   • Risankizumab 1

4. IL-12/23 inhibitor:

   • Ustekinumab 1

5. CTLA4 inhibitor:

   • Abatacept 1

Targeted Synthetic DMARDs (tsDMARDs):

1. JAK inhibitors:

   • Tofacitinib
   • Upadacitinib 1

2. PDE4 inhibitor:

   • Apremilast 1

Evidence Quality and Nuances

The 2024 EULAR guidelines 1 represent the most current international consensus, incorporating 36 expert opinions and systematic literature review through April 2023. This supersedes the 2022 GRAPPA recommendations 2.

Key evidence considerations:

• Level 1B evidence supports anti-TNF efficacy for signs, symptoms, and radiographic progression 3
• No difference in efficacy was found for PDE4 inhibitors, TNF inhibitors, IL-17 inhibitors, IL-12/23 inhibitors, IL-23 inhibitors, and JAK inhibitors in subgroups with or without concurrent csDMARDs 2
• Safety concern: JAK inhibitors carry worldwide cautionary warnings following large RCT data in rheumatoid arthritis showing increased cardiovascular and malignancy risks 1

Domain-Specific Considerations

Multi-domain disease (most common presentation) requires treatment selection addressing all active domains simultaneously 2. Treatment is typically driven by the most severe or impactful domain.

For predominant skin disease: IL-17 and IL-23 inhibitors may offer superior skin efficacy compared to joint-focused agents 4

For axial involvement: TNF inhibitors and IL-17 inhibitors have stronger evidence 5

Treatment Persistence

Real-world data shows 12-month persistence probability of 51.2% for b/tsDMARDs 6. Factors associated with discontinuation include:

• Female sex (increased risk)
• Baseline fatigue (increased risk)
• Psoriasis co-diagnosis (decreased risk - better persistence) 6

Common Pitfalls to Avoid

1. Delayed escalation: Do not continue ineffective csDMARD therapy beyond 24 weeks without reassessment
2. Ignoring comorbidities: Cardiovascular disease, malignancy history, and infection risk should guide biologic selection
3. Undertreating skin disease: Address both joint and skin manifestations simultaneously
4. JAK inhibitor positioning: Given safety signals, reserve for patients who have failed other options or have specific contraindications to biologics 1

Dosing Patterns

For secukinumab: 300 mg every 4 weeks is the most common maintenance dose (60.4% of patients), though 150 mg every 4 weeks is used in 34.1% 6

For ixekizumab: 80 mg every 4 weeks is standard (84.4% of patients), with dose escalation to 160 mg every 4 weeks in select cases (10.4%) 6